Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Intravenous immunoglobulin (IVIg) ameliorates disease in a murine model of anti-laminin 332 mucous membrane pemphigoid

ABSTRACT: Intravenous immunoglobulin (IVIg) is used to treat mucous membrane pemphigoid (MMP), although its therapeutic effectivity is not sufficiently supported by randomized controlled clinical trials and its mode of action is only insufficiently understood. We have examined the effect of IVIg in a mouse model of anti-laminin 332 MMP and found that IVIg ameliorates both cutaneous and mucosal inflammatory lesions. Our investigation into the modes of action of IVIg in MMP indicated effective antiinflammatory mechanisms beyond the enhanced degradation of IgG mediated through inhibition of the neonatal Fc receptor. Our results suggest that IVIg curbs the activation of neutrophils at several levels. This includes a direct, immediate inhibitory effect on neutrophil activation by immune complexes but not C5a which blunts the release of reactive oxygen species and leukotriene B4 from neutrophils. IVIg also suppresses the formation of neutrophil extracellular traps in response to Ca2+ ionophore. In vivo treatment with IVIg altered the transcriptome of blood leukocytes and bone marrow neutrophils towards less proinflammatory phenotypes. Collectively, our results support the effectivity of IVIg in the treatment of MMP and indicate that effects on neutrophils at multiple levels may significantly contribute to its therapeutic effects.

ORGANISM(S): Mus musculus

PROVIDER: GSE263026 | GEO | 2024/04/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Effect of IVIG on the activation of plasmacytoid dendritic cells

Project description:To investigate the effect of IVIG and desialylated IVIG on the activation of plasmacytoid dendritic cells (pDCs). Human primary plasmacytoid dendritic cells were treated with TLR stimulation together with or without IVIG or desialylated IVIG, and the change of genes were analyzed. Primary human pDCs were preincubated with or without 10mg/ml IVIG or desialylated IVIG followed by stimulation with CpG overnight. The different genes between IVIG+CpG and desialylated IVIG+CpG were analyzed.

2022-07-04 | GSE207028 | GEO

Identification of IVIg regulated genes in human peripheral blood monocytes by gene expression analysis before and after IVIg infusion in CVID patients [CD3]

Project description:Identification of IVIg regulated genes in human peripheral blood monocytes by gene expression analysis before and after IVIg infusion in CVID patients

2022-05-03 | GSE158573 | GEO

Identification of IVIg regulated genes in human peripheral blood B cells by gene expression analysis before and after IVIg infusion in CVID patients [CD20]

Project description:Identification of IVIg regulated genes in human peripheral blood B cells by gene expression analysis before and after IVIg infusion in CVID patients

2022-05-03 | GSE158576 | GEO

Transcript abundance patterns in Kawasaki disease patients IVIG-resistance

Project description:We compared the abundance of gene transcripts of whole blood RNA between IVIG-resistant and –responsive KD patients to identify biomarkers that might differentiate between these two groups and to generate new targets for therapies in IVIG-resistant KD patients.

2009-10-17 | GSE18606 | GEO

Identification of IVIg regulated genes in human peripheral blood monocytes from Common Variable Immunodeficiency patients (CVID) [CD14+]

Project description:Identification of IVIg regulated genes in human peripheral blood monocytes by gene expression analysis before and after IVIg infusion in CVID patients

2022-05-03 | GSE133907 | GEO

Identification of IVIg regulated genes in human peripheral blood mononuclear cells from Common Variable Immunodeficiency patients (CVID) [PMBC]

Project description:Identification of IVIg regulated genes in human PBMC by gene expression analysis before and after IVIg infusion in CVID patients.

2022-05-03 | GSE133835 | GEO

Study on the treatment of ITP mice with IVIG sourced from distinct sex-special plasma (DSP-IVIG)

Project description:Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the treatment of autoimmune diseases (AID), especially immune thrombocytopenia (ITP). Since significant differences exist in protein types and expression levels between male and female plasma, and the prevalence of autoimmune diseases varies between sexes. The present study seeks to explore potential variations in IVIG sourced from distinct sex-specific plasma (DSP-IVIG), including IVIG sourced from female plasma (F-IVIG), IVIG sourced from male plasma (M-IVIG), and IVIG sourced from a blend of male and female plasma (Mix-IVIG). We investigate whether these IVIG variants exhibit different effects in the treatment of ITP. To address this question, we established an ITP mouse model treated with DSP IVIG.

2023-09-26 | PXD045681 | iProX

Gene expression profiles in nineteen Kawasaki Disease (KD) patients before and after intravenous immunoglobulin (IVIG) treatment

Project description:In this study, we compared global gene expressions between pre- and post- intravenous immunoglobulin (IVIG) administration in nineteen Kawasaki disease (KD) patients. Peripheral blood mononuclear cells (PBMCs) obtained from nineteen patients before and after IVIG treatment was extracted using a PAXgene blood RNA isolation kit. Amplified cRNAs of each patient were analyzed using with Agilent Whole Human Genome Microarray 4x44K G4112F array.

2017-09-19 | GSE73577 | GEO

Genome wide analysis of gene expression in conjunctiva whole tissue and primary conjunctival fibroblasts from patients with ocular mucous membrane pemphigoid and control patients

Project description:Identification of differentially expressed genes in conjunctiva and conjuntival fibroblasts from pemphigoid patients compared to control patients. Results indicate these differentially expressed genes, which could be further investigated as potential anti-fibrosis targets

2016-01-29 | GSE77361 | GEO

Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19

Project description:While critical for host defense, innate immune cells are also pathologic drivers of acute respiratory distress syndrome (ARDS). Innate immune dynamics during COVID-19 ARDS, compared to ARDS from other respiratory pathogens, is unclear. Moreover, mechanisms underlying beneficial effects of dexamethasone during severe COVID-19 remain elusive. Using scRNA-seq and plasma proteomics, we discovered that compared to bacterial ARDS, COVID-19 was associated with expansion of distinct neutrophil states characterized by interferon (IFN) and prostaglandin (PG) signalling. Dexamethasone during severe COVID-19 depleted circulating neutrophils, altered IFNactive neutrophils, downregulated interferon-stimulated gene, and activated IL1R2+ve neutrophils. Dexamethasone also expanded immunosuppressive immature neutrophils and remodeled cellular interactions by changing neutrophils from information receivers into information providers. Male patients had higher proportions of IFNactive neutrophils, preferential steroid-induced immature neutrophil expansion, and possibly different effects on outcome. Our single-cell atlas (www.biernaskielab.ca/COVID_neutrophil) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.

2021-10-05 | GSE157789 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data